Abstract:Abstract Background Alzheimer's disease (AD) is a multifactorial disease, with ongoing amyloid and tau accumulation, axonal damage and astrocytosis. Blood‐based biomarkers reflecting these processes are potentially valuable for patient selection for clinical trials, for monitoring disease progression and treatment effects, and for the differential diagnosis of AD. Several studies have shown that plasma amyloid beta (Abeta) 42 and 40 concentrations, phosphorylated tau (pTau) at amino acid 181 or 217, neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) are changed in AD. Therefore, our studies are driven by the idea that combination of several markers will provide a more complete picture of the full complexity of AD. Method The results presented were obtained in several retrospective clinical cohort studies in memory clinics. Plasma Abeta 42 and 40, GFAP, and NfL were measured with Simoa technology, using homebrew assays (Amyblood, ADx), and commercial kits (Quanterix). pTau181 and 217 were measured using MSD technology with Lilly antibodies. Based on positive Amyblood and GFAP results, a novel 4‐plex assay was developed (AUMC, Quanterix, ADx). Results will be presented on the use pTau217 and of the measurement of combinations of Abeta isoforms, GFAP, and NfL for differential diagnosis of AD, Lewy body dementia, and Frontotemporal lobar degeneration (FTLD). Result The plasma markers are analyzed in over 1100 subjects. The Abeta 42/40 ratio decreased 1.2 fold in cases in the AD spectrum with a positive amyloid‐PET status, compared to amyloid negative cases. pTau181 concentrations were increased 2.4 fold in cases with tau accumulation measured with FTP‐PET, and pTau181 was increased 2.3 fold in AD compared to FTLD. NfL was increased 1.4‐2.3 fold in AD and FTLD patients compared to controls. GFAP levels were increased 1.8 fold in amyloid‐PET cases. Combining GFAP and the Abeta 42/40 ratio together with APOE e4 carriership resulted in an AUC of 88% differentiating amyloid‐PET positive from negative cases. Conclusion Individual blood‐based biomarkers reflect different physiological processes in the brain. Creating a panel of t markers could provide a more complete picture of ongoing pathological processes and likely increases diagnostic accuracy to be suitable for blood‐based screening of AD and enable personalized medicine.

Neurodegenerative biomarkers in different chambers of the eye relative to plasma: an agreement validation study

Diagnostic Value of Isolated Plasma Biomarkers and Its Combination in Neurodegenerative Dementias: A Multicenter Cohort Study

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

[Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease]

Plasma glial fibrillary acidic protein, neurofilament light, phosphorylated‐tau‐181 and amyloid β42/40 as prognostic biomarkers for clinical progression to dementia in individuals with subjective cognitive decline and mild cognitive impairment

Evaluation of serum NFL, T-tau, p-tau181, p-tau217, Aβ40 and Aβ42 for the diagnosis of neurodegenerative diseases

Amyloid, pTau, NfL, and GFAP as biomarkers for Alzheimer’s disease

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia

Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer’s Disease

Plasma tau and neurofilament light chain as biomarkers of Alzheimer's disease and their relation to cognitive functions

Targeted proteomic profiling in cerebrospinal fluid and plasma identifies biomarkers for Alzheimer’s disease

Diagnostic Blood Biomarkers in Alzheimer’s Disease

Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease

Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer's Disease Progression

Tau, Glial Fibrillary Acidic Protein, and Neurofilament Light Chain as Brain Protein Biomarkers in Cerebrospinal Fluid and Blood for Diagnosis of Neurobiological Diseases

Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy

Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline

Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative

Biomarkers for Alzheimer’s Disease Early Diagnosis

Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression

Neurodegenerative fluid biomarkers are enriched in human cervical lymph nodes